<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>monoclonal antibodies Archives - Hubu.news</title>
	<atom:link href="https://hubu.news/tag/monoclonal-antibodies/feed/" rel="self" type="application/rss+xml" />
	<link>https://hubu.news/tag/monoclonal-antibodies/</link>
	<description>Germany &#38; Europe</description>
	<lastBuildDate>Thu, 05 Jan 2023 10:26:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://hubu.news/wp-content/uploads/2022/03/cropped-PNG3-32x32.png</url>
	<title>monoclonal antibodies Archives - Hubu.news</title>
	<link>https://hubu.news/tag/monoclonal-antibodies/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Alarming Antibody Evasion Properties of Rising SARS-CoV-2 Variants Raise Concerns for Vaccine Efficacy</title>
		<link>https://hubu.news/2023/alarming-antibody-evasion-properties-of-rising-sars-cov-2-variants-raise-concerns-for-vaccine-efficacy/</link>
		
		<dc:creator><![CDATA[Torsten]]></dc:creator>
		<pubDate>Thu, 05 Jan 2023 10:26:29 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Mixed]]></category>
		<category><![CDATA[ACE2-binding affinity]]></category>
		<category><![CDATA[antibodies]]></category>
		<category><![CDATA[antibody evasion]]></category>
		<category><![CDATA[antigenic distance]]></category>
		<category><![CDATA[antigenic drift]]></category>
		<category><![CDATA[antigenic leap]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[BA.2]]></category>
		<category><![CDATA[BA.4/BA.5]]></category>
		<category><![CDATA[BA.5]]></category>
		<category><![CDATA[bebtelovimab]]></category>
		<category><![CDATA[bivalent mRNA vaccine]]></category>
		<category><![CDATA[BQ]]></category>
		<category><![CDATA[BQ.1]]></category>
		<category><![CDATA[BQ.1.1]]></category>
		<category><![CDATA[breakthrough infections]]></category>
		<category><![CDATA[casirivimab]]></category>
		<category><![CDATA[cilgavimab]]></category>
		<category><![CDATA[clinical use]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid-19]]></category>
		<category><![CDATA[D614G]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[Emergency]]></category>
		<category><![CDATA[Emergency Use Authorization]]></category>
		<category><![CDATA[etesevimab]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Evusheld]]></category>
		<category><![CDATA[G252V mutation]]></category>
		<category><![CDATA[G446S]]></category>
		<category><![CDATA[growth advantage]]></category>
		<category><![CDATA[hACE2]]></category>
		<category><![CDATA[imdevimab]]></category>
		<category><![CDATA[immunocompromised individuals]]></category>
		<category><![CDATA[infected persons]]></category>
		<category><![CDATA[K444T]]></category>
		<category><![CDATA[K444T mutation]]></category>
		<category><![CDATA[monoclonal antibodies]]></category>
		<category><![CDATA[monoclonal antibody therapeutics]]></category>
		<category><![CDATA[monovalent mRNA vaccine]]></category>
		<category><![CDATA[mRNA vaccine]]></category>
		<category><![CDATA[N460K]]></category>
		<category><![CDATA[N460K mutation]]></category>
		<category><![CDATA[neutralizing monoclonal antibody]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[NTD]]></category>
		<category><![CDATA[Omicron]]></category>
		<category><![CDATA[Omicron variant]]></category>
		<category><![CDATA[point mutants]]></category>
		<category><![CDATA[Q183E]]></category>
		<category><![CDATA[R346T]]></category>
		<category><![CDATA[R346T mutation]]></category>
		<category><![CDATA[RBD]]></category>
		<category><![CDATA[RBD class 1]]></category>
		<category><![CDATA[RBD class 2]]></category>
		<category><![CDATA[RBD class 3]]></category>
		<category><![CDATA[re-infections]]></category>
		<category><![CDATA[receptor binding affinity]]></category>
		<category><![CDATA[sarbecoviruses]]></category>
		<category><![CDATA[SARS-CoV-2]]></category>
		<category><![CDATA[SARS-CoV-2 Omicron]]></category>
		<category><![CDATA[serum neutralizing titers]]></category>
		<category><![CDATA[sotrovimab]]></category>
		<category><![CDATA[spike mutations]]></category>
		<category><![CDATA[spike protein]]></category>
		<category><![CDATA[subvariants]]></category>
		<category><![CDATA[tixagevimab]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[V445P]]></category>
		<category><![CDATA[vaccinees]]></category>
		<category><![CDATA[WA1/BA.5 bivalent vaccine]]></category>
		<category><![CDATA[XBB]]></category>
		<category><![CDATA[XBB.1]]></category>
		<guid isPermaLink="false">https://hubu.news/?p=8717</guid>

					<description><![CDATA[<p>BQ and XBB subvariants show marked impairment in neutralization by sera from vaccine recipients and infected individuals, including&#8230;</p>
<p>The post <a href="https://hubu.news/2023/alarming-antibody-evasion-properties-of-rising-sars-cov-2-variants-raise-concerns-for-vaccine-efficacy/">Alarming Antibody Evasion Properties of Rising SARS-CoV-2 Variants Raise Concerns for Vaccine Efficacy</a> appeared first on <a href="https://hubu.news">Hubu.news</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
